Harvard Bioscience earnings release, August 11, 2026

Harvard Bioscience Inc (HBIO) · Form 8-K, Item 2.02 · Filed · SEC filing

Harvard Bioscience Announces Second Quarter 2026 Financial Results

HOLLISTON, Mass., August 11, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience,

Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the second quarter ended June 30, 2026.

"We delivered a strong quarter anchored by 11% top-line growth, reflective of stronger demand and an improved environment across our key customer channels,” said John Duke, President and Chief Executive

Officer. “We are seeing solid commercial traction across our telemetry and cellular and molecular technology (CMT) products, driven by our AAA and electroporation businesses, and strong engagement from researchers utilizing our preclinical platform. Outperformance in our CMT products and China drove a slight mix impact on adjusted gross margin. This strong sales momentum positions us to raise our full-year revenue outlook while maintaining our adjusted EBITDA target, supported by ongoing cost discipline and operational progress.”

Second Quarter 2026 Results

For the second quarter of 2026, the Company reported revenues of $22.7 million compared to $20.5 million in the second quarter of 2025. Revenue for the second quarter of 2026 included a favorable impact from foreign currency exchange rates of approximately 1%, using a constant currency basis. Gross profit for the second quarter of 2026 was

$12.6 million compared to $11.5 million in the second quarter of 2025. Gross margin for the second quarter of 2026 was 55.6%, compared to 56.4% in the second quarter of 2025.

Adjusted gross profit and adjusted gross margin for the second quarter of 2026 was $12.9 million and 56.7%, respectively, compared with $11.7 million and 57.2% in the same period of the prior year.

Net loss for the second quarter of 2026 was ($2.9) million, compared to a net loss of ($2.3) million in the second quarter of 2025. Adjusted EBITDA for the second quarter of 2026 was $1.7 million compared to

$1.5 million in the second quarter of the prior year.

Six Months Ended June 30, 2026 Results

For the six months ended June 30, 2026, the Company reported revenues of $43.5 million, compared to $42.2 million in the same period of the prior year. Revenue for the six months ended June 30, 2026, included a favorable impact from foreign currency exchange rates of approximately 2%, using a constant currency basis. Gross profit was

$24.9 million for the first six months of 2026 compared to $23.7 million in the same period of the prior year. Gross margin for the six months ended June 30, 2026, was 57.2% compared with 56.2% in the same period of the prior year.

Adjusted gross profit and adjusted gross margin for the six months ended June 30, 2026, was $25.3 million and 58.3%, respectively, compared with $24.1 million and 57.0% in the same period of the prior year.

Net loss for the six months ended June 30, 2026, was ($6.3) million compared to a net loss of ($52.6) million in the same period of the prior year, primarily due to goodwill impairment in the first quarter of 2025 of $48.0 million. Adjusted EBITDA for the six months ended June 30, 2026, was $2.4 million, compared to adjusted EBITDA of $2.3 million for the same period of the prior year. Cash (used in) provided by operations was ($0.3) million during the six months ended June 30, 2026 compared to $5.7 million in the same period of the prior year.

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, see

“Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Third Quarter 2026 Guidance

The Company’s third quarter outlook reflects expected mid-single-digit year-over-year revenue growth at the midpoint of guidance, driven by expected ongoing demand across CMT and new product innovation (NPI) platforms and improving year-over-year profitability on an adjusted EBITDA basis. The Company expects:

Full Year 2026 Guidance

The Company is raising its full-year 2026 revenue guidance to reflect expected strong CMT portfolio momentum and continued adoption of its NPI pipeline, while updating its full-year adjusted gross margin target to account for expected higher-volume of lower-margin CMT product and geographic mix. The Company now expects:

Webcast and Conference Call Details

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company’s Investor Relations website shortly before the webcast begins.

Analysts who would like to join the call and ask a question must register here

( https://register-conf.media-server.com/register/BI5dd1769394494366b6d31b0ceabeb4cc).

Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here (https://investor.harvardbioscience.com/events-and-presentations).

Use of Non-GAAP Financial Information

In this press release we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted gross margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, net debt, adjusted gross profit, and non-GAAP revenue on a constant currency basis. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses... (truncated)re reflective of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, restructuring charges, other operating expenses, goodwill impairment, interest and other expense, net, income taxes, and the tax impact of reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

Historical non-GAAP financial information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure, which is included below. In addition, the forward-looking Adjusted gross margin and Adjusted EBITDA guidance for the third quarter of 2026 and full-year 2026 excludes potential charges or gains that may be recorded during the fiscal year, including among other things, restructuring and reorganization expenses, and non-GAAP restructuring related expenses.

The Company has not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be misleading to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different from other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations.

With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Financial statements

Income Statement

investors@harvardbioscience.com (Unaudited, in thousands, except per share data)

HARVARD BIOSCIENCE, INC. – Condensed Consolidated Statements Of Operations – (Unaudited, in thousands, except per share data) – Three Months Ended June 30, – 2026HARVARD BIOSCIENCE, INC. – Condensed Consolidated Statements Of Operations – (Unaudited, in thousands, except per share data) – Three Months Ended June 30, – 2025HARVARD BIOSCIENCE, INC. – Condensed Consolidated Statements Of Operations – (Unaudited, in thousands, except per share data) – Six Months Ended June 30, – 2026HARVARD BIOSCIENCE, INC. – Condensed Consolidated Statements Of Operations – (Unaudited, in thousands, except per share data) – Six Months Ended June 30, – 2025
Revenues22,72720,45043,48242,224
Cost of revenues10,0978,91718,60818,507
Gross profit12,63011,53324,87423,717
Sales and marketing expenses5,4004,53910,7359,510
General and administrative expenses4,6174,2629,3199,447
Research and development expenses2,4532,1894,7794,510
Amortization of intangible assets8201,1621,6402,322
Goodwill impairment47,951
Other operating expenses318200553464
Total operating expenses13,60812,35227,02674,204
Operating loss-978-819-2,152-50,487
Other expense:Interest expense-1,793-1,001-3,521-1,934
Other expense:Other expense, net-125-434-530-627
Other expense:Total other expense-1,918-1,435-4,051-2,561
Other expense:Loss before income taxes-2,896-2,254-6,203-53,048
Other expense:Income tax expense (benefit)1428131-426
Other expense:Net loss-2,910-2,282-6,334-52,622
Loss per share:Basic and diluted loss per share *-0.64-0.52-1.41-11.91
Weighted-average common shares:Basic and diluted *4,5264,4304,4844,420

Income Statement

HARVARD BIOSCIENCE, INC. — * Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026. (in thousands, except per share data and percentages)

HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Three Months Ended – June 30, 2026HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Three Months Ended – June 30, 2025HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Six Months Ended – June 30, 2026HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Six Months Ended – June 30, 2025
GAAP operating loss-978-819-2,152-50,487
Stock-based compensation3804726371,072
Acquired asset amortization8201,1621,6402,322
Goodwill impairment47,951
Other operating expenses (1)318200553464
Other adjustments (2)5793067142
Adjusted operating income1,1191,0451,3491,364
Operating margin-4.3%-4.0%-4.9%-119.6%
Adjusted operating margin4.9%5.1%3.1%3.2%
GAAP net loss-2,910-2,282-6,334-52,622
Stock-based compensation3804726371,072
Acquired asset amortization8201,1621,6402,322
Goodwill impairment47,951
Other operating expenses (1)318200553464
Other adjustments (2)5793067142
Income taxes190183716-16
Adjusted net (loss) income-623-235-2,117-787
Depreciation & amortization5494561,086950
Interest and other expense, net (2) (3)1,9181,4354,0512,561
Adjusted income taxes (4)-177-156-579-410
Adjusted EBITDA1,6671,5002,4352,314
Adjusted EBITDA margin7.3%7.3%5.6%5.5%
Diluted loss per share (GAAP)-0.64-0.52-1.41-11.91
Diluted adjusted (loss) earnings per share-0.14-0.05-0.47-0.18
Weighted-average common shares:Diluted GAAP *4,5264,4304,4844,420
Weighted-average common shares:Diluted Adjusted *4,5264,4304,4844,420

Income Statement

HARVARD BIOSCIENCE, INC. (in thousands, except per share data and percentages)

HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Three Months Ended June 30, – 2026HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Three Months Ended June 30, – 2025HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Growth RatesHARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Six Months Ended June 30, – 2026HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Six Months Ended June 30, – 2025HARVARD BIOSCIENCE, INC. – Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) – Growth Rates
Total revenues22,72720,45011.1%43,48242,2243.0%
Effects of foreign currency rate fluctuations-153-791
Revenue on a constant currency basis22,57420,45010.4%42,69142,2241.1%

Income Statement

Three Months Ended June 30, (in thousands)

Three Months Ended June 30, – 2026 – AmountThree Months Ended June 30, – 2026 – MarginThree Months Ended June 30, – 2025 – AmountThree Months Ended June 30, – 2025 – MarginSix Months Ended June 30, – 2026 – AmountSix Months Ended June 30, – 2026 – MarginSix Months Ended June 30, – 2025 – AmountMargin
Gross profit12,63055.6%11,53356.4%24,87457.2%23,71756.2%
Adjustments:Stock-based compensation expense - cost of sales150.1%310.2%210.0%610.1%
Adjustments:Depreciation and amortization - cost of sales1950.9%1380.7%3990.9%2840.7%
Adjustments:Other adjustments - cost of sales440.2%0.0%450.1%0.0%

Balance Sheet

HARVARD BIOSCIENCE, INC. — * Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026. (Unaudited, in thousands, except share and per share data)

HARVARD BIOSCIENCE, INC. – Condensed Consolidated Balance Sheets – (Unaudited, in thousands, except share and per share data) – June 30, 2026HARVARD BIOSCIENCE, INC. – Condensed Consolidated Balance Sheets – (Unaudited, in thousands, except share and per share data) – December 31, 2025
AssetsCash and cash equivalents6,5038,614
AssetsAccounts receivable, net14,50016,043
AssetsInventories22,23020,805
AssetsOther current assets3,2302,763
AssetsTotal current assets46,46348,225
AssetsProperty, plant and equipment5,3474,787
AssetsGoodwill and other intangibles15,55017,198
AssetsOther long-term assets8,9269,861
AssetsTotal assets76,28680,071
Liabilities and Stockholders' EquityOther current liabilities24,79321,960
Liabilities and Stockholders' EquityTotal current liabilities24,79321,960
Liabilities and Stockholders' EquityLong-term debt, net36,68235,870
Liabilities and Stockholders' EquityOther long-term liabilities7,3938,507
Liabilities and Stockholders' EquityStockholders’ equity7,41813,734
Liabilities and Stockholders' EquityTotal liabilities and stockholders’ equity76,28680,071

Cash Flow

HARVARD BIOSCIENCE, INC. — * Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026. (in thousands)

HARVARD BIOSCIENCE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited, in thousands) – Six Months Ended – June 30, 2026HARVARD BIOSCIENCE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited, in thousands) – Six Months Ended – June 30, 2025
Cash flows from operating activities:Net loss-6,334-52,622
Cash flows from operating activities:Adjustments to operating cash flows4,21352,062
Cash flows from operating activities:Changes in operating assets and liabilities1,7846,301
Cash flows from operating activities:Net cash (used in) provided by operating activities-3375,741
Cash flows from investing activities:Additions to property, plant and equipment-1,114-602
Cash flows from investing activities:Acquisition of intangible assets-422-314
Cash flows from investing activities:Net cash used in investing activities-1,536-916
Cash flows from financing activities:Repayment of term debt-2,000
Cash flows from financing activities:Payment of debt issuance costs-131-433
Cash flows from financing activities:Proceeds from exercise of warrants and stock purchase plan15046
Cash flows from financing activities:Taxes paid related to net share settlement of equity awards-66-75
Cash flows from financing activities:Net cash used in financing activities-47-2,462
Cash flows from financing activities:Effect of exchange rate changes on cash and cash equivalents-191971
Cash flows from financing activities:(Decrease) increase in cash and cash equivalents-2,1113,334
Cash flows from financing activities:Cash and cash equivalents at the beginning of period8,6144,108
Cash flows from financing activities:Cash and cash equivalents at the end of period6,5037,442
Full release

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,”

“estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, adjusted gross margin, adjusted EBITDA, gross margin, cash and debt position, balance sheet, growth, adoption and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic conditions. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk

Factors” section of the Company’s most recently filed Annual Report on Form 10-K, as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Investor Inquiries:

Mark Frost

Chief Financial Officer

(508) 893-3120 investors@harvardbioscience.com

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

(1) Other operating expenses for the three months ended June 30, 2026 includes $318 thousand of restructuring-related charges compared to $30 thousand of restructuring-related charges and $170 thousand of employee retention tax credit fees for the three months ended June 30, 2025. Other operating expenses for the six months ended June 30, 2026 includes $553 thousand of restructuring-related charges compared to $123 thousand of restructuring-related charges and $341 thousand related to ERTC Fees for the six months ended June 30, 2025

(2) Other adjustments for the three months ended

June 30, 2026 includes $579 thousand of Non-GAAP restructuring-related charges compared to $30 thousand of Non-GAAP restructuring-related charges for the three months ended June 30, 2025. Other adjustments for the six months ended June 30, 2026 includes $671 thousand of

Non-GAAP restructuring-related charges compared to $42 thousand of Non-GAAP restructuring-related charges for the six months ended June 30, 2025

(3) Interest expense for the three months ended June 30, 2026... (truncated)hs ended June 30, 2025. Interest expense for the six months ended June 30,

2026 was $3.5 million,compared to $1.9 million for the six months ended June 30, 2025.

(4) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

(1) Other adjustments - cost of sales for the three months ended June 30, 2026 includes $44 thousand of Non-GAAP restructuring-related charges compared to $1 thousand of Non-GAAP restructuring-related charges. Other adjustments - cost of sales for the six months ended June 30, 2026 includes $45 thousand of Non-GAAP restructuring-related charges.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harvard Bioscience earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.